CAL 02

Drug Profile

CAL 02

Alternative Names: CAL02

Latest Information Update: 02 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LASCCO
  • Class Antibacterials
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Community-acquired pneumonia

Most Recent Events

  • 22 Apr 2017 Initial adverse events data from a phase I trial in Community-acquired pneumonia presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 22 Apr 2017 Pharmacodynamic data from preclinical studies presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 01 Mar 2016 Phase-I clinical trials in Community-acquired pneumonia (In the elderly, In adults) in Belgium and France (IV) (NCT02583373)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top